● Recruiting

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Condition: Leiomyosarcoma · Soft-tissue Sarcomas · Sponsor: M.D. Anderson Cancer Center

PhasePhase 1

Planned participants18

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas.

This description comes directly from the study's public registry record.

Talk to the study team

Elise Nassif, MD · (281) 460-0607 · efnassif@mdanderson.org

Gracy Zacharian, BSN,MSN,RN · (713) 792-2669 · gzachari@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06308419